ARHGAP8 Activators
ARHGAP8 Activators are a diverse set of chemical compounds that indirectly enhance the functional activity of ARHGAP8 through modulation of various signaling pathways that govern the actin cytoskeleton dynamics and cellular tension. Forskolin, by raising cAMP levels, indirectly augments ARHGAP8's role in the cell by activating PKA and influencing actin cytoskeleton dynamics, where ARHGAP8 is a central regulator. The ROCK inhibitors Y-27632, H-1152, GSK269962A, and Fasudil each contribute to this enhancement by diminishing RhoA-mediated contractility, thus allowing ARHGAP8 to exert its Rho GTPase inactivation more effectively. NSC23766 and ITX3 target the upstream regulators of Rho GTPases, Rac1, and RhoG, respectively, therebyshifting the intracellular balance of Rho GTPase activity towards the inhibitory function of ARHGAP8. ML141 and CASIN impede Cdc42, reinforcing ARHGAP8's negative regulation of RhoA signaling and contributing to the regulation of actin cytoskeleton reorganization. Exoenzyme C3, by inactivating RhoA, B, and C, synergizes with ARHGAP8's ability to modulate actin dynamics due to less competition from active Rho GTPases.
The functional activity of ARHGAP8 is further influenced by compounds that modulate transcriptional responses and kinase activity linked to actin cytoskeleton remodeling. CCG-1423 suppresses RhoA-driven transcription by targeting the MRTF/SRF pathway, which can indirectly accentuate the role of ARHGAP8 in actin remodeling. SD-208's inhibition of TGF-βRI kinase activity may also support ARHGAP8 activity by affecting pathways that influence cellular tension and morphology, processes that are regulated by ARHGAP8's GAP activity. Collectively, these ARHGAP8 Activators, by targeting different aspects of Rho GTPase signaling and related cellular mechanisms, facilitate the enhancement of ARHGAP8-mediated functions in cytoskeletal organization and cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, leading to increased cAMP levels that enhance ARHGAP8 activity by promoting PKA-mediated signaling events. PKA activation may influence actin cytoskeleton dynamics, which ARHGAP8 is known to modulate. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that indirectly enhances ARHGAP8 function by reducing the downstream RhoA-mediated contractility, thus potentially favoring ARHGAP8-mediated Rho GTPase inactivation and actin cytoskeleton reorganization. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 inhibitor that indirectly enhances ARHGAP8 function by diminishing Cdc42-mediated signaling pathways, potentially allowing for a relative increase in ARHGAP8's inhibitory action on RhoA GTPase. | ||||||
GSK 269962 | 850664-21-0 | sc-363279 sc-363279A | 10 mg 50 mg | $300.00 $1000.00 | 1 | |
GSK269962A, another ROCK inhibitor, might enhance ARHGAP8's function by decreasing RhoA-mediated contractile signaling, which ARHGAP8 regulates through its GTPase-activating protein activity. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 inhibits RhoA-mediated transcription by blocking the MRTF/SRF pathway. This inhibition can enhance ARHGAP8's role in actin cytoskeleton remodeling by reducing RhoA-driven cellular responses. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208 is a TGF-βRI kinase inhibitor that may enhance ARHGAP8 activity by altering actin cytoskeleton remodeling and cellular tension, processes in which ARHGAP8 is involved through its Rho GTPase-activating function. | ||||||
CASIN | 425399-05-9 | sc-397016 | 10 mg | $460.00 | 1 | |
CASIN inhibits Cdc42, which can enhance ARHGAP8 activity by shifting the balance of Rho GTPase signaling towards RhoA inhibition, a core function of ARHGAP8 in cytoskeletal dynamics. | ||||||